Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism

Amar, Laurence, Azizi, Michel, Menard, Joël, Peyrard, Séverine, Watson, Catherine, Plouin, Pierre-François · 2010 · Hypertension

Abstract

We report the first administration of an orally active aldosterone synthase inhibitor, LCI699, to 14 patients with primary aldosteronism. After a 2-week placebo run-in, patients received oral LCI699 (0.5 mg BID) for 2 weeks, LCI699 (1.0 mg BID) for 2 weeks, and placebo for 1 week. We assessed changes in hormone concentrations, plasma potassium levels, and 24-hour ambulatory systolic blood pressure and safety. The supine plasma aldosterone concentration decreased from 540 pmol/L (95% CI: 394 to 739 pmol/L) to 171 pmol/L (95% CI: 128 to 230 pmol/L) after 0.5 mg of LCI699 (−68%; P <0.0001) and to 133 pmol/L (95% CI: 100 to 177 pmol/L) after 1.0 mg of LCI699 (−75%; P <0.0001). Plasma 11-deoxycorticosterone concentrations increased by 710% after 0.5 mg of LCI699 ( P <0.0001) and by 1427% after 1.0 mg of LCI699 ( P <0.0001). The plasma potassium concentration increased from 3.27±0.31 to 4.03±0.33 mmol/L ( P <0.0001) after only 1 week on 0.5 mg of LCI699. Twenty-four–hour ambulatory systolic blood pressure decreased by −4.1 mm Hg (95% CI: −8.1 to −0.1 mm Hg) after 4 weeks of treatment ( P =0.046). Basal plasma cortisol concentrations remained unchanged, whereas plasma adrenocorticotropic hormone concentrations increased by 35% after 0.5 mg of LCI699 ( P =0.08) and by 113% after 1.0 mg of LCI699 ( P <0.0001), and the plasma cortisol response to an adrenocorticotropic hormone test was blunted. All of the variables except plasma 11-deoxycorticosterone concentration returned to initial levels after the placebo. LCI699 was well tolerated. In conclusion, the administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism. This 4-week treatment corrected the hypokalemia and mildly decreased blood pressure. The effects on the glucocorticoid axis were consistent with a latent inhibition of cortisol synthesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hypertensionaha.110.157271

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 202

Metadata

Authors
Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C., & Plouin, P.-F.
Venue
Hypertension
Published
2010-11
Volume
56
Issue
5
Pages
831-838
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W2148589377
Cited by
202
References
4
FWCI
11.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism. https://app.cochat.ai/papers/10.1161/hypertensionaha.110.157271
The paper
Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C., & Plouin, P.-F. (2010). Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism. Hypertension. https://doi.org/10.1161/hypertensionaha.110.157271

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.